EP1187606A1 - Pharmaceutical composition containing sibutramine and orlistat - Google Patents

Pharmaceutical composition containing sibutramine and orlistat

Info

Publication number
EP1187606A1
EP1187606A1 EP00940379A EP00940379A EP1187606A1 EP 1187606 A1 EP1187606 A1 EP 1187606A1 EP 00940379 A EP00940379 A EP 00940379A EP 00940379 A EP00940379 A EP 00940379A EP 1187606 A1 EP1187606 A1 EP 1187606A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
treatment
obesity
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00940379A
Other languages
German (de)
French (fr)
Inventor
David John Heal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of EP1187606A1 publication Critical patent/EP1187606A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to a method for treating and preventing co-morbid conditions associated with obesity and to products and pharmaceutical compositions suitable for use in such a method. More particularly, the invention relates to a method for the treatment of co-morbid conditions associated with obesity by the administration of sibutramine or a salt or a metabolite thereof and orlistat and to products and compositions containing such compounds.
  • Sibutramine hydrochloride monohydrate and orlistat are both currently being developed for use in the treatment of obesity.
  • the two compounds however, achieve weight loss through entirely different mechanisms.
  • Sibutramine is a 5-hydroxytryptamine and noradrenaline reuptake inhibitor in vivo (Buckett, W.R., Thomas, P.C. & Luscombe, G.P. (1988). Prog. Neuro- Psychopharmacol. Biol. Psychiat. 12, 575-584 and Luscombe, G.P., Hopcroft, R.H., Thomas, P.C. & Buckett, W.R. (1989). Neurophar acology, 28, 129-134.) Studies have shown that it reduces body weight by a dual mode of action; it decreases food intake by enhancing satiety (Fantino, M. & Souquet, A.-M. (1995). Int. J.
  • Orlistat inhibits iipase enzymes which are responsible for breaking down ingested fat (Borgstrom, B. (1988). Biochem. Biophys. Acta. 962 (3), 308-316); as a consequence of this, unabsorbed fat is egested in the faeces.
  • the present invention provides a method for the treatment of co- morbid conditions associated with obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of formula I
  • the present invention may provide the following advantages. Firstly, the beneficial effect achieved is greater than that achieved by the sole administration of either a compound of formula I or compound II. Secondly, a synergistic effect is achieved in which the benefit obtained by the administration of a compound of formula I and the compound of formula II to a first test group is greater than the total benefit achieved by administration of the compound of formula I to a second test group and the benefit achieved by administration of compound II to a third test group. Thirdly, when the benefit obtained after administration of either a compound of formula I or the compound II has reached a plateau, a further benefit is achieved by administering the other compound. Fourthly, lower doses of the compound of formula I and the compound of formula II may be used in the present invention thus reducing the side-effects associated with administration of a higher dose of each compound.
  • co-morbid conditions associated with obesity means medical conditions known to those skilled in the art to be associated with obesity.
  • the term includes but is not limited to the following: diabetes including non-insulin dependent diabetes mellitus, impaired glucose tolerance, hypertension, coronary thrombosis, stroke, depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, cerebral ischaemia, obsessive- compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, lipid syndromes, hyperglycaemia, hyperlipidaemia, and stress in mammals particularly humans.
  • diabetes including non-insulin dependent diabetes mellitus, impaired glucose tolerance, hypertension, coronary thrombosis, stroke, depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, cerebral ischaemia, obsessive- compulsive behaviour, panic attacks,
  • the present invention may be useful in the treatment or prevention of metabolic diseases and conditions arising therefrom, for example non exercise activity thermogenesis and increased metabolic rate, sexual dysfunction, sleep apnoea, premenstrual syndrome, urinary incontinence including stress incontinence, hyperactivity disorders, hiatial hernia and reflux esophagitis, pain, especially neuropathic pain, weight gain associated with drug treatment, chronic fatigue syndrome, osteoarthritis and gout, cancers associated with weight gain, menstrual dysfunction, gallstones, orthostatic hypotension and pulmonary hypertension.
  • metabolic diseases and conditions for example non exercise activity thermogenesis and increased metabolic rate, sexual dysfunction, sleep apnoea, premenstrual syndrome, urinary incontinence including stress incontinence, hyperactivity disorders, hiatial hernia and reflux esophagitis, pain, especially neuropathic pain, weight gain associated with drug treatment, chronic fatigue syndrome, osteoarthritis and gout, cancers associated with weight gain, menstrual dysfunction, gallstones, ortho
  • the present invention may be useful in preventing cardiovascular disease, and in reducing platelet adhesiveness, in aiding weight loss after pregnancy.reducing the craving to smoke and in aiding weight loss after smoking cessation.
  • the present invention may also be useful in lowering uric acid levels and lipid levels in mammals particularly humans.
  • a preferred compound of formula I is N- ⁇ 1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyl ⁇ -N,N-dimethylamine or a salt thereof, for example the hydrochloride salt, known as sibutramine hydrochloride.
  • a preferred form of this hydrochloride is its monohydrate, known as sibutramine hydrochloride monohydrate.
  • N- ⁇ 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl ⁇ -N,N-dimethylamine hydrochloride in the treatment of obesity is described in European Patent Number 397831.
  • a particularly preferred form of this compound is N- ⁇ 1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutyl ⁇ -N,N-dimethylamine hydrochloride monohydrate (sibutramine hydrochloride monohydrate) which is described in European Patent Number 230742.
  • the compound of formula II has the chemical name (2S, 3S, 5S)-5-[(S)-2- formamido-4-methylvaleryloxy]-2-hexyl-3-hydroxyhexadecanoic acid lactone. It is also known as "N-formyl-L-leucine, ester with (3S, 4S)-3-hexyl-4-[(2S)-2-hydroxy- tridecyl]-2-oxetanone", (-)-tetrahydrolipstatin, tetrahydrolipistatin, and orlistat.
  • orlistat in the control or prevention of obesity and hyperlipaemia is described in US Patent 4598089 (Hoffmann-La Roche Inc.).
  • a process for the preparation of orlistat is described in US Patent 4983746 (Hoffmann- La Roche Inc.).
  • a composition comprising orlistat and acarbose is described in EP638317 (Hoffmann-La Roche AGF).
  • the enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, for example silica with a bound chiral ligand or in the presence of a chiral solvent.
  • enantiomers of secondary and tertiary amines of formula I can also be prepared by preparing the primary amine racemate, resolving this mixture into its individual enantiomers and then converting the relevant optically pure primary amine enantiomer into the desired secondary or tertiary amine product.
  • Preferred compounds of formula I are N- ⁇ 1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyl ⁇ -N, N-dimethylamine, N- ⁇ 1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl ⁇ - N- methylamine, and N-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine including racemates, individual enantiomers and mixtures thereof, and pharmaceutically acceptable salts thereof.
  • a compound of formula I and the compound of formula II may be administered concomitantly or concurrently, for example in the form of separate dosage units to be used simultaneously, separately or sequentially.
  • the present invention provides a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R-i and R 2 are independently H or methyl and the compound of formula II for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
  • the present invention provides a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R 1 and R 2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of co- morbid conditions associated with obesity.
  • the present invention provides a product containing a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R ⁇ and R 2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
  • the present invention provides the use of a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R-i and R 2 are independently H or methyl in the manufacture of a medicament for the treatment of co-morbid conditions associated with obesity in a patient who is also receiving treatment with orlistat.
  • the present invention provides a method of treating co- morbid conditions associated with obesity comprising the administration of an adjunctive therapy comprising a therapeutically effective amount of a compound of formula I and orlistat to a patient in need thereof.
  • the invention also provides the use of the above combination of drugs in the manufacture of a medicament for the treatment of co-morbid conditions associated with obesity. Additionally, it provides the combination for use in the treatment of co- morbid conditions associated with obesity.
  • the amount of each compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound of formula I to be administered will be in the range 0.1 to 50 mg preferably 1 to 30 mg per day given in one or more doses and more preferably 10 mg, 15 mg, 20 mg, 25 mg or 30 mg per day and most preferably 20 mg.
  • the dosage of orlistat to be administered will be in the range of 50 to 1440 mg given in one or more doses, preferably three times daily, more preferably in the range of 120 to 720 mg and most preferably in the range of 120 to 360 mg .
  • the compound of formula I preferably sibutramine hydrochloride monohydrate, may be administered in any of the known pharmaceutical dosage forms. Orlistat is preferably administered orally.
  • sibutramine hydrochloride monohydrate is administered once daily, preferably first thing in the morning, and orlistat is administered three times daily either with or before meals.
  • the dose of sibutramine hydrochloride monohydrate is 20 mg or 30 mg administered once daily and the dose of orlistat is 120 mg administered three times daily either with or before meals.
  • the dose of sibutramine hydrochloride monohydrate is given prior to the first dose of orlistat, preferably in the range of30 minutes to 3 hours, for example 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours or 3 hours, before the first dose of orlistat.
  • Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions.
  • the excipients used in the preparation of these compositions are the excipients known in the pharmacist's art.
  • Tablets may be prepared from a mixture of the active compounds with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods.
  • the tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate.
  • the tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention.
  • Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate.
  • capsules for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner.
  • the contents of the capsule may be formulated using known methods so as to give sustained release of the active compound.
  • the tablets and capsules may conveniently each contain 1 to 50 mg of the compound of formula I and 1 to 360 mg of orlistat.
  • dosage forms for oral administration include, for example, aqueous suspensions containing the active compounds in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy-methylcellulose, and oily suspensions containing the active compounds in a suitable vegetable oil, for example arachis oil.
  • the active compounds may be formulated into granules with or without additional excipients.
  • the granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion.
  • the granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.
  • the compounds of formula I and orlistat may be formulated into a composition which the patient retains in his mouth so that the active compounds are administered through the mucosa of the mouth.
  • Dosage forms of the compounds of formula I suitable for rectaladministration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
  • Dosage forms of the compounds of formula I suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.
  • Dosage forms of the compounds of formula I for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally.
  • a suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol.
  • the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base.
  • the amount of each active compound contained in a topical formulation should be such that a therapeutically effective amount of each compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
  • the compounds of formula I may be formulated into a composition which is dispersed as an aerosol into the patients oral or nasal cavity.
  • Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.
  • the compound of formula I may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body.
  • Internal sources include implanted reservoirs containing the compounds to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the compounds to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compounds to be infused.
  • the support may be a single body containing all the compounds or a series of several bodies each containing part of the compounds to be delivered.
  • the amount of active compounds present in an internal source should be such that a therapeutically effective amount of each compound is delivered over a long period of time.
  • the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.
  • the active compounds may, if desired, be associated with other compatible pharmacologically active ingredients.
  • vitamin supplements may be administered with the compounds of the present invention.
  • compositions incorporating both a compound of formula I and orlistat are important embodiments of the present invention.
  • Such pharmaceutical compositions contain a therapeutically effective amount of each of the compounds.
  • Each dosage unit may contain the daily doses of both compounds, or may contain a fraction of the daily dose, such as one-third of the doses.
  • each dosage unit may contain the entire dose of one of the compounds, and a fraction of the dose of the other compound. In such case, the patient would daily take one of the combination dosage units, and one or more units containing only the other compound.
  • capsules 10 parts by weight of active compound and 240 parts by weight of lactose are de-aggregated and blended. The mixture is filled into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound.
  • Tablets are prepared from the following ingredients.
  • the active compound, the lactose and some of the starch are de-aggregated, blended and the resulting mixture is granulated with a solution of the polyvinylpyrrolidone in ethanol.
  • the dry granulate is blended with the magnesium stearate and the rest of the starch.
  • the mixture is then compressed in a tabletting machine to give tablets each containing a unit dose or a part of a unit dose of active compound. Enteric coated tablets
  • Tablets are prepared by the method described in (b) above.
  • the tablets are enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1 :1).
  • suppositories 100 parts by weight of active compound is incorporated in 1300 parts by weight of triglyceride suppository base and the mixture formed into suppositories each containing a therapeutically effective amount of active ingredient.
  • Hard gelatin capsules are prepared using the following ingredients:
  • a tablet is prepared using the ingredients below:
  • the components are blended and compressed to form tablets each weighing 545 mg.
  • a compound of formula I is administered to a first test group
  • a compound of formula II is administered to a second test group
  • a combination of a compound of formula I and a compound of formula II is administered to a third test group with appropriate controls to eliminate the effects of the dosing vehicles used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for the treatment of co-morbid conditions associated with obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of formula (I) including enantiomers and pharmaceutically acceptable salts thereof, in which R1 and R2 are independently H or methyl, and a therapeutically effective amount of a compound of formula (II) wherein the compound of formula (I) and the compound of formula (II) are administered simultaneously, separately or sequentially.

Description

PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT
This invention relates to a method for treating and preventing co-morbid conditions associated with obesity and to products and pharmaceutical compositions suitable for use in such a method. More particularly, the invention relates to a method for the treatment of co-morbid conditions associated with obesity by the administration of sibutramine or a salt or a metabolite thereof and orlistat and to products and compositions containing such compounds.
Sibutramine hydrochloride monohydrate and orlistat are both currently being developed for use in the treatment of obesity. The two compounds, however, achieve weight loss through entirely different mechanisms.
Sibutramine is a 5-hydroxytryptamine and noradrenaline reuptake inhibitor in vivo (Buckett, W.R., Thomas, P.C. & Luscombe, G.P. (1988). Prog. Neuro- Psychopharmacol. Biol. Psychiat. 12, 575-584 and Luscombe, G.P., Hopcroft, R.H., Thomas, P.C. & Buckett, W.R. (1989). Neurophar acology, 28, 129-134.) Studies have shown that it reduces body weight by a dual mode of action; it decreases food intake by enhancing satiety (Fantino, M. & Souquet, A.-M. (1995). Int. J. Obesity, 19, 145; Halford, J.C.G., Heal, D.J. & Blundell, J.E. (1995). Brit. J. Pharmacol. 114, 387P; and Stricker-Krongrad, A., Souquet, A.-M. & Burlet, C. (1995). Int. J. Obesity, 19, 145.), and it increases energy expenditure by stimulating thermogenesis (Connoley, I. P., Heal, D.J. & Stock, M J. (1995). Brit. J. Pharmacol. 114, 388P; and Connoley, I P., Frost, I., Heal, D.J. & Stock, M.J. (1996). Brit. J. Pharmacol. 117, 170P).
Orlistat inhibits iipase enzymes which are responsible for breaking down ingested fat (Borgstrom, B. (1988). Biochem. Biophys. Acta. 962 (3), 308-316); as a consequence of this, unabsorbed fat is egested in the faeces.
It has been reported that orlistat should not be combined with appetite suppressants ( The New York Times May 15 1997) . Surprisingly, it has now been found that co-administration of sibutramine hydrochloride monohydrate and orlistat results in beneficial effects with respect to weight-loss. Accordingly, the present invention provides a method for the treatment of co- morbid conditions associated with obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of formula I
including enantiomers and pharmaceutically acceptable salts thereof, in which R, and R2 are independently H or methyl, and a therapeutically effective amount of a compound of formula II
wherein the compound of formula I and the compound of formula II are administered simultaneously, separately or sequentially.
The present invention may provide the following advantages. Firstly, the beneficial effect achieved is greater than that achieved by the sole administration of either a compound of formula I or compound II. Secondly, a synergistic effect is achieved in which the benefit obtained by the administration of a compound of formula I and the compound of formula II to a first test group is greater than the total benefit achieved by administration of the compound of formula I to a second test group and the benefit achieved by administration of compound II to a third test group. Thirdly, when the benefit obtained after administration of either a compound of formula I or the compound II has reached a plateau, a further benefit is achieved by administering the other compound. Fourthly, lower doses of the compound of formula I and the compound of formula II may be used in the present invention thus reducing the side-effects associated with administration of a higher dose of each compound.
The term "co-morbid conditions associated with obesity" as used in this document means medical conditions known to those skilled in the art to be associated with obesity. The term includes but is not limited to the following: diabetes including non-insulin dependent diabetes mellitus, impaired glucose tolerance, hypertension, coronary thrombosis, stroke, depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, cerebral ischaemia, obsessive- compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, lipid syndromes, hyperglycaemia, hyperlipidaemia, and stress in mammals particularly humans.
In addition the present invention may be useful in the treatment or prevention of metabolic diseases and conditions arising therefrom, for example non exercise activity thermogenesis and increased metabolic rate, sexual dysfunction, sleep apnoea, premenstrual syndrome, urinary incontinence including stress incontinence, hyperactivity disorders, hiatial hernia and reflux esophagitis, pain, especially neuropathic pain, weight gain associated with drug treatment, chronic fatigue syndrome, osteoarthritis and gout, cancers associated with weight gain, menstrual dysfunction, gallstones, orthostatic hypotension and pulmonary hypertension.
The present invention may be useful in preventing cardiovascular disease, and in reducing platelet adhesiveness, in aiding weight loss after pregnancy.reducing the craving to smoke and in aiding weight loss after smoking cessation. The present invention may also be useful in lowering uric acid levels and lipid levels in mammals particularly humans.
A preferred compound of formula I is N-{1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyl}-N,N-dimethylamine or a salt thereof, for example the hydrochloride salt, known as sibutramine hydrochloride. A preferred form of this hydrochloride is its monohydrate, known as sibutramine hydrochloride monohydrate. The preparation and use of compounds of formula I, such as N-{1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine and salts thereof, in the treatment of depression is described in British Patent Specification 2098602. The use of compounds of formula I such as N-{1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyl}-N,N-dimethylarnine and salts thereof in the treatment of Parkinson's disease is described in published PCT application WO 88/06444. The use of N-{1- [1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine and salts thereof in the treatment of cerebral function disorders is described in US Patent 4939175. The use of N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride in the treatment of obesity is described in European Patent Number 397831. A particularly preferred form of this compound is N-{1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride monohydrate (sibutramine hydrochloride monohydrate) which is described in European Patent Number 230742. The use of N-{1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyl}-N,N-dimethylamine and salts thereof for improving the glucose tolerance of humans having Impaired Glucose Tolerance or Non-Insulin Dependent Diabetes Mellitus is described in published PCT application WO95/20949.
The compound of formula II has the chemical name (2S, 3S, 5S)-5-[(S)-2- formamido-4-methylvaleryloxy]-2-hexyl-3-hydroxyhexadecanoic acid lactone. It is also known as "N-formyl-L-leucine, ester with (3S, 4S)-3-hexyl-4-[(2S)-2-hydroxy- tridecyl]-2-oxetanone", (-)-tetrahydrolipstatin, tetrahydrolipistatin, and orlistat.
The extraction and use of orlistat in the control or prevention of obesity and hyperlipaemia is described in US Patent 4598089 (Hoffmann-La Roche Inc.). A process for the preparation of orlistat is described in US Patent 4983746 (Hoffmann- La Roche Inc.). A composition comprising orlistat and acarbose is described in EP638317 (Hoffmann-La Roche AGF).
It will be appreciated by those skilled in the art that compounds of formula I contain a chiral centre. When a compound of formula I contains a single chiral centre it may exist in two enantiomeric forms. The present invention includes the use of the individual enantiomers and mixtures of the enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesised by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation. Enantiomers of secondary and tertiary amines of formula I can also be prepared by preparing the primary amine racemate, resolving this mixture into its individual enantiomers and then converting the relevant optically pure primary amine enantiomer into the desired secondary or tertiary amine product.
Preferred compounds of formula I are N-{1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyl}-N, N-dimethylamine, N-{1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}- N- methylamine, and N-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine including racemates, individual enantiomers and mixtures thereof, and pharmaceutically acceptable salts thereof. Specific enantiomers offormula I are (+)- N-{1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N, N-dimethylamine, (-)-N-{1 -[1 -(4- chlorophenyl) cyclobutyl]-3-methylbutyl}-N,N-dimethylamine, (R)-(+)-N-{1-[1-(4- chlorophenyl) cyclobutyl]-3-methylbutyl}-N-methylamine, (S)-(-)-N-{1 -[1 -(4- chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine, (R)-(+)-1 -[1 -(4-chloro- phenyl)cyclobutyl]-3-methylbutylamine and (S)-(-)-1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine.
In the method of the present invention a compound of formula I and the compound of formula II may be administered concomitantly or concurrently, for example in the form of separate dosage units to be used simultaneously, separately or sequentially. In another aspect the present invention provides a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R-i and R2 are independently H or methyl and the compound of formula II for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
In yet another aspect the present invention provides a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R1 and R2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of co- morbid conditions associated with obesity.
In a further aspect the present invention provides a product containing a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R^ and R2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
In yet another aspect the present invention provides the use of a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R-i and R2 are independently H or methyl in the manufacture of a medicament for the treatment of co-morbid conditions associated with obesity in a patient who is also receiving treatment with orlistat.
In a further aspect, the present invention provides a method of treating co- morbid conditions associated with obesity comprising the administration of an adjunctive therapy comprising a therapeutically effective amount of a compound of formula I and orlistat to a patient in need thereof.
The invention also provides the use of the above combination of drugs in the manufacture of a medicament for the treatment of co-morbid conditions associated with obesity. Additionally, it provides the combination for use in the treatment of co- morbid conditions associated with obesity. The amount of each compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound of formula I to be administered will be in the range 0.1 to 50 mg preferably 1 to 30 mg per day given in one or more doses and more preferably 10 mg, 15 mg, 20 mg, 25 mg or 30 mg per day and most preferably 20 mg. The dosage of orlistat to be administered will be in the range of 50 to 1440 mg given in one or more doses, preferably three times daily, more preferably in the range of 120 to 720 mg and most preferably in the range of 120 to 360 mg . The compound of formula I, preferably sibutramine hydrochloride monohydrate, may be administered in any of the known pharmaceutical dosage forms. Orlistat is preferably administered orally.
In a preferred aspect of the present invention sibutramine hydrochloride monohydrate is administered once daily, preferably first thing in the morning, and orlistat is administered three times daily either with or before meals. Preferably the dose of sibutramine hydrochloride monohydrate is 20 mg or 30 mg administered once daily and the dose of orlistat is 120 mg administered three times daily either with or before meals. Most preferably the dose of sibutramine hydrochloride monohydrate is given prior to the first dose of orlistat, preferably in the range of30 minutes to 3 hours, for example 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours or 3 hours, before the first dose of orlistat.
In another aspect of to the present invention there is provided a pharmaceutical composition comprising a compound of formula I
CH,
I
including enantiomers and pharmaceutically acceptable salts thereof, in which R, and R2 are independently H or methyl, and the compound of formula II
in conjunction with a pharmaceutically acceptable diluent or carrier.
Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art. Tablets may be prepared from a mixture of the active compounds with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods. The tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate. The tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner. The contents of the capsule may be formulated using known methods so as to give sustained release of the active compound. The tablets and capsules may conveniently each contain 1 to 50 mg of the compound of formula I and 1 to 360 mg of orlistat.
Other dosage forms for oral administration include, for example, aqueous suspensions containing the active compounds in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy-methylcellulose, and oily suspensions containing the active compounds in a suitable vegetable oil, for example arachis oil. The active compounds may be formulated into granules with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion. The granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.
The compounds of formula I and orlistat may be formulated into a composition which the patient retains in his mouth so that the active compounds are administered through the mucosa of the mouth.
Dosage forms of the compounds of formula I suitable for rectaladministration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
Dosage forms of the compounds of formula I suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.
Dosage forms of the compounds of formula I for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally. A suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol. Alternatively the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base. The amount of each active compound contained in a topical formulation should be such that a therapeutically effective amount of each compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
The compounds of formula I may be formulated into a composition which is dispersed as an aerosol into the patients oral or nasal cavity. Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.
The compound of formula I may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body. Internal sources include implanted reservoirs containing the compounds to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the compounds to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compounds to be infused. The support may be a single body containing all the compounds or a series of several bodies each containing part of the compounds to be delivered. The amount of active compounds present in an internal source should be such that a therapeutically effective amount of each compound is delivered over a long period of time.
In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.
In the compositions of the present invention the active compounds may, if desired, be associated with other compatible pharmacologically active ingredients. Optionally vitamin supplements may be administered with the compounds of the present invention.
Pharmaceutical compositions incorporating both a compound of formula I and orlistat are important embodiments of the present invention. Such pharmaceutical compositions contain a therapeutically effective amount of each of the compounds. Each dosage unit may contain the daily doses of both compounds, or may contain a fraction of the daily dose, such as one-third of the doses. Alternatively, each dosage unit may contain the entire dose of one of the compounds, and a fraction of the dose of the other compound. In such case, the patient would daily take one of the combination dosage units, and one or more units containing only the other compound.
The use of compounds of the present invention in the manufacture of '•> pharmaceutical compositions is illustrated by the following description. In this description the term "active compound" denotes either or both compounds of the invention unless otherwise stated.
a) Capsules
In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose are de-aggregated and blended. The mixture is filled into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound.
b) Tablets
Tablets are prepared from the following ingredients.
Parts by weight Active compound 10
Lactose 190
Maize starch 22
Polyvinylpyrrolidone 10
Magnesium stearate 3
The active compound, the lactose and some of the starch are de-aggregated, blended and the resulting mixture is granulated with a solution of the polyvinylpyrrolidone in ethanol. The dry granulate is blended with the magnesium stearate and the rest of the starch. The mixture is then compressed in a tabletting machine to give tablets each containing a unit dose or a part of a unit dose of active compound. Enteric coated tablets
Tablets are prepared by the method described in (b) above. The tablets are enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1 :1).
d) Suppositories (Compound of formula I only)
In the preparation of suppositories, 100 parts by weight of active compound is incorporated in 1300 parts by weight of triglyceride suppository base and the mixture formed into suppositories each containing a therapeutically effective amount of active ingredient.
Formulation 1
Hard gelatin capsules are prepared using the following ingredients:
Formulation 2
A tablet is prepared using the ingredients below:
The components are blended and compressed to form tablets each weighing 545 mg.
The advantages of the present invention may be demonstrated by animal models or clinical trials as known to those skilled in the art. Suitable animal models and methods for clinical trials may be found in :
(1 ). "New Antidiabetic drugs" Eds CJ Bailey & PR Flatt 1990 Smith-Gordan and company Ltd, UK
(2). "Obesity" Eds P Bjorntorp & BN Brodoff, 1992, JB Lippincott Company,
Philadelphia, USA and
(3). "Obesity: Trends and Treatments" S Parker 1996 Scrip Report, PJB Publications
Ltd and references therein.
Studies are performed in which a compound of formula I is administered to a first test group, a compound of formula II is administered to a second test group, a combination of a compound of formula I and a compound of formula II is administered to a third test group with appropriate controls to eliminate the effects of the dosing vehicles used.
A statistical analysis of the effects achieved in each group provides results demonstrating the advantage of the present invention.

Claims

Claims
1 ) A method for the treatment of co-morbid conditions associated with obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of formula I
CH,
I
including enantiomers and pharmaceutically acceptable salts thereof, in which R-, and R2 are independently H or methyl, and a therapeutically effective amount of a compound of formula II
wherein the compound of formula I and the compound of formula II are administered simultaneously, separately or sequentially.
2) A method according to claim 1 in which the compound of formula I is N-{1- [1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N, N-dimethylamine or a salt thereof.
3) A method according to claim 2 wherein the compound of formula I is administered 30 minutes to 3 hours prior to the administration of the compound of formula II.
4) A compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R-i and R2 are independently H or methyl and the compound of formula II for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity. 5) A compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R^ and R2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
6) A product containing a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R-| and R2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
7) The use of a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R^ and R2 are independently H or methyl in the manufacture of a medicament for the treatment of co-morbid conditions associated with obesity in a patient who is also receiving treatment with orlistat.
8) A pharmaceutical composition comprising a compound of formula
including enantiomers and pharmaceutically acceptable salts thereof, in which R^ and R2 are independently H or methyl, and the compound of formula II
in conjunction with a pharmaceutically acceptable diluent or carrier.
EP00940379A 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat Withdrawn EP1187606A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
GB9914744 1999-06-24
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
EP1187606A1 true EP1187606A1 (en) 2002-03-20

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00940379A Withdrawn EP1187606A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Country Status (21)

Country Link
EP (1) EP1187606A1 (en)
JP (1) JP2003503349A (en)
KR (1) KR20020015357A (en)
CN (1) CN1358092A (en)
AU (1) AU5533200A (en)
BG (1) BG106180A (en)
BR (1) BR0011880A (en)
CA (1) CA2375972A1 (en)
CZ (1) CZ20014613A3 (en)
GB (1) GB9914744D0 (en)
HK (1) HK1049278A1 (en)
HU (1) HUP0201878A3 (en)
IL (1) IL147079A0 (en)
MX (1) MXPA01012936A (en)
NO (1) NO20016224L (en)
PL (1) PL352402A1 (en)
RU (1) RU2229289C2 (en)
SK (1) SK18242001A3 (en)
TR (1) TR200103699T2 (en)
WO (1) WO2001000205A1 (en)
ZA (1) ZA200109989B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
JP2008517976A (en) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング A pharmaceutical composition for the treatment of diabetes mellitus type 1, obesity and related symptoms, comprising a CB1 cannabinoid receptor antagonist and a potassium channel opener
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
KR20080046601A (en) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 Sibutramine-containing clathrate with excellent storage stability
CN101890017A (en) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 Medicament composition containing sibutramine and stanin fat-reducing medicament and application thereof
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX336980B (en) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combination and composition for treating obesity.
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
RU2119156C1 (en) * 1996-06-05 1998-09-20 Открытое акционерное общество "Киришинефтеоргсинтез" Device for diagnosing state of crude oils from electrical conductance
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0100205A1 *

Also Published As

Publication number Publication date
PL352402A1 (en) 2003-08-25
MXPA01012936A (en) 2004-04-21
ZA200109989B (en) 2003-02-26
JP2003503349A (en) 2003-01-28
CN1358092A (en) 2002-07-10
AU5533200A (en) 2001-01-31
NO20016224L (en) 2002-02-12
HK1049278A1 (en) 2003-05-09
RU2229289C2 (en) 2004-05-27
WO2001000205A1 (en) 2001-01-04
KR20020015357A (en) 2002-02-27
NO20016224D0 (en) 2001-12-19
BR0011880A (en) 2002-03-19
GB9914744D0 (en) 1999-08-25
TR200103699T2 (en) 2002-04-22
IL147079A0 (en) 2002-08-14
HUP0201878A3 (en) 2005-04-28
SK18242001A3 (en) 2003-02-04
HUP0201878A2 (en) 2003-08-28
CZ20014613A3 (en) 2003-04-16
CA2375972A1 (en) 2001-01-04
BG106180A (en) 2002-08-30

Similar Documents

Publication Publication Date Title
AU773188C (en) Method of treating eating disorders
US6403641B2 (en) Therapeutic agents
US6376552B1 (en) Treatment of gallstones
EP1187606A1 (en) Pharmaceutical composition containing sibutramine and orlistat
US6441046B1 (en) Control of metabolism
WO2001000187A2 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
US6403650B1 (en) Treatment of pulmonary hypertension
EP1169027A1 (en) Treatment of osteoarthritis
WO2000056316A1 (en) Treatment of gallstones
WO2000056308A1 (en) Prevention of cardiovascular disease
MXPA00006201A (en) Pharmaceutical composition containing sibutramine and orlistat
WO2000056317A1 (en) Weight loss after pregnancy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20011220;LV PAYMENT 20011220;MK;RO PAYMENT 20011220;SI PAYMENT 20011220

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT GMBH & CO. KG

17Q First examination report despatched

Effective date: 20040312

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051231